PubRank

G A Otterson

Author PubWeight™ 31.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev 1998 3.01
2 A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002 2.42
3 Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996 2.30
4 MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 2008 2.15
5 Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014 1.97
6 DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001 1.45
7 Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene 2001 1.30
8 The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol 1995 1.14
9 Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia 2001 1.14
10 Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene 1994 1.12
11 RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994 1.12
12 Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995 1.04
13 Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 2012 1.03
14 Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 1997 1.02
15 A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012 1.01
16 Functional analysis at the Cys706 residue of the retinoblastoma protein. J Biol Chem 1992 0.98
17 Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein. Mol Cell Biol 1994 0.96
18 A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004 0.96
19 CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 1995 0.88
20 RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 1998 0.86
21 RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. Cell Growth Differ 1993 0.85
22 Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol 2008 0.83
23 An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun 2009 0.80
24 Localization of STCH to human chromosome 21q11.1. Genomics 1995 0.79
25 RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques 2002 0.78
26 Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 1993 0.75